Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.
Fiche publication
Date publication
avril 2012
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Pr NERICH Virginie, Pr PIVOT Xavier, Dr CURTIT Elsa, Dr THIERY-VUILLEMIN Antoine, Dr DEMARCHI Martin
Tous les auteurs :
Curtit E, Chaigneau L, Pauchot J, Nguyen T, Nerich V, Bazan F, Thiery-Vuillemin A, Demarchi M, Pivot X, Villanueva C
Lien Pubmed
Résumé
Anthracycline extravasation is an uncommon but very serious complication. Very few data are available in the literature concerning the consequences and the management of extravasation of liposomal doxorubicin. This report describes the cases of two patients with liposomal doxorubicin extravasation who developed irritant reaction without vesicant or necrotic lesions. It is concordant with other cases described in the literature and suggests that extravasation of liposomal doxorubicin can be relatively well tolerated. The process applied to extravasations of irritant and non-vesicant agents could be used to manage extravasations of liposomal doxorubicin.
Mots clés
Aged, Doxorubicin, adverse effects, Extravasation of Diagnostic and Therapeutic Materials, Female, Humans, Irritants, adverse effects, Middle Aged
Référence
Anticancer Res.. 2012 Apr;32(4):1481-3